证券代码：301047 证券简称：义翘神州 公告编号：2025-020 北京义翘神州科技股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 （1）现场会议时间：2025 年 5 月 9 日（星期五）14:30。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025 年 5 月 9 日 9:15-9:25、9:30-11:30 和 13:00-15:00；通过深圳证券交 易所互联网投票系统投票的具体时间为：2025 年 5 月 9 日 9:15-15:00 期间的任 意时间。 （二）会议召开方式：本次股东大会采取现场投票与网络投票相结合的方式。 （三）会议召开地点：北京市北京经济技术开发区科创十街 18 号院 11 号楼 215 会议室。 （四）会议召集人：公司董事会。 （五）会议主持人：公司董事长谢良志博士。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过决议的情况。 一、会议召开情况 （一）会议召开时间 （六）本次会议的召集、召开与表决 ...

证券代码：301047 证券简称：义翘神州 公告编号：2025-021 北京义翘神州科技股份有限公司 关于注销回购股份减少注册资本 暨通知债权人的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、通知债权人的原由 北京义翘神州科技股份有限公司（以下简称"公司"）于 2024 年 8 月 1 日召 开 2024 年第二次临时股东大会，审议通过了《关于 2024 年第二期回购公司股份 方案的议案》，同意公司使用自有资金以集中竞价方式回购股份用于注销并减少 公司注册资本。自 2024 年 8 月 20 日首次回购股份至 2024 年 11 月 27 日实施完 毕，公司累计回购股份数量为 4,533,890 股，占注销前公司总股本的 3.59%。注 销后，公司总股本由 126,170,632 股减少至 121,636,742 股，公司注册资本由人民 币 126,170,632 元减少至人民币 121,636,742 元。公司于 2025 年 5 月 9 日召开 2024 年年度股东大会，审议通过了《关于减少注册资本并修订<公司章程>的议案》 等议案，同意公司减 ...

Group 1: Financial Performance - The company's CRO service revenue for 2022 was 109.6 million with a gross margin of 66.96% [4] - In 2023, CRO service revenue increased to 154.1 million with a gross margin of 69.62% [4] - However, in 2024, CRO service revenue rose to 168.5 million but the gross margin dropped to 47.58%, indicating a decline of over 20 percentage points [4] Group 2: Market Challenges and Strategies - The company faced a negative growth in CRO service revenue in the second half of 2024 due to market competition and price adjustments [2] - To mitigate the impact of increased tariffs between the US and China, the company has enhanced local warehousing and inventory measures while leveraging its US and Canadian production capabilities [3] - The company aims to improve service competitiveness and expand overseas CRO business to achieve growth in 2025 [2] Group 3: Business Development and Future Outlook - The company expects its conventional business revenue to continue growing in 2025, despite uncertainties in unconventional business revenue due to external factors [3] - The dry powder culture medium business is anticipated to generate revenue starting in 2025 after initial customer trials in 2024 [5] - The company plans to enhance the utilization of the Skyland Industrial Square, acquired for over 900 million, to support the biopharmaceutical industry chain in the capital [5] Group 4: Product Development and Innovation - The company is actively developing biological reagents related to organoid research, including matrix gels, although there are currently no plans for traditional matrix gel products due to animal use requirements [7] - New products such as salt-tolerant nucleic acid enzymes and linking enzymes have been launched by the Suzhou subsidiary, which is still in the process of market expansion [6]

Group 1 - The core viewpoint of the news is that the private equity firm, Phan Hou Wei Ran, has conducted research on a listed company, Yiqiao Shenzhou, focusing on its strategies in response to complex international situations and tariff changes [1] - Yiqiao Shenzhou has adopted proactive inventory measures and leveraged its production capabilities in the US and Canada to support overseas operations [1] - The company is optimizing its team and enhancing automation in its subsidiaries, with a steady development of its business in Taizhou and a need for time to accumulate project experience in its Suzhou subsidiary [1] Group 2 - The overseas development strategy of Yiqiao Shenzhou emphasizes product complementarity and localized production, particularly in Japan, South Korea, and Europe and the US [1] - The company plans to continue investments and acquisitions in areas such as reagents, consumables, automation equipment, and synthetic biology, focusing on complementary product technology capabilities [1] - The CRO business will prioritize quality improvement, efficiency enhancement, and technological upgrades to ensure reasonable profits [1] Group 3 - Phan Hou Wei Ran (Shanghai) Asset Management Co., Ltd. was established in 2014 and is focused on domestic and foreign stock trading strategies and fund management [2] - The company aims to provide long-term stable value-added wealth management services to high-net-worth clients and institutions [2] - As of July 2020, the company had issued 48 private equity funds, with 18 currently in operation and an asset management scale of approximately 800 million RMB [2]

Financial Performance - In 2024, the company achieved a revenue of 613.67 million yuan, a decrease of 5.06% year-on-year, with conventional business revenue at 533.10 million yuan, an increase of 10.54% [3] - Non-conventional business revenue was 54.19 million yuan, down 63.55% year-on-year; net profit attributable to shareholders was 121.93 million yuan, a decrease of 53.13% [3] - In Q1 2025, the company reported a revenue of 155.30 million yuan, an increase of 8.61% year-on-year; non-conventional business revenue was 4.95 million yuan, down 63.42% [3] - Net profit for Q1 2025 was 22.64 million yuan, a decrease of 48.27% year-on-year, primarily due to fluctuations in financial returns and rising operational costs [3] Business Strategy and Development - The company is actively responding to changes in tariff policies by utilizing local warehousing resources and enhancing inventory measures [4] - Investments in subsidiaries in Suzhou and Taizhou have not yet yielded scale benefits, with ongoing efforts to optimize local teams and automate processes [4] - Focus on overseas development includes establishing a subsidiary in South Korea and enhancing local sales efforts in Japan and South Korea [5] - The company aims to leverage geographical advantages in the U.S. and Canada for localized production and market expansion [5] Investment and M&A Plans - The company is pursuing investments and acquisitions in areas such as reagents, consumables, automation equipment, and synthetic biology [5] - Future acquisitions will prioritize complementary product technology capabilities and focus on upstream and downstream enterprises related to the company's business [5] - The company emphasizes the importance of reasonable valuation in investment decisions to effectively control risks [5] CRO Business Direction - The CRO business is facing profit pressure due to market demand changes and increased competition [7] - The company plans to enhance quality and efficiency through technology upgrades and process optimization to improve project success rates and reduce costs [7] - Resource allocation will be strategically balanced to achieve revenue and profit goals across different service types [7]

中信证券股份有限公司关于 北京义翘神州科技股份有限公司持续督导 保荐总结报告书 | | | 一、发行人基本情况 | 发行人名称 | 北京义翘神州科技股份有限公司 | | --- | --- | | 法定代表人 | 张杰 | | 证券简称 | 义翘神州 | | 证券代码 | 301047.SZ | | 上市交易所 | 深圳证券交易所 | | 股份总数 | 12,163.6742万股 | | 注册地址 | 北京市北京经济技术开发区景园街8号院1号楼9层B901 | | 办公地址 | 北京市北京经济技术开发区科创十街18号院11号楼 | | 邮政编码 | 100176 | | 网址 | www.sinobiological.com | | 电子信箱 | ir@sinobiological.cn | 二、本次发行情况概述 持续督导期内，保荐人及保荐代表人严格按照《证券发行上市保荐业务管理 办法》《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司自 律监管指引第13号——保荐业务》的相关规定，承担持续督导发行人履行规范运 作、信守承诺、信息披露等义务，具体包括： 1、督导公司完善法人治理结构，有效执行并完善 ...

关于北京义翘神州科技股份有限公司 2024 年度持续督导工作现场检查报告 | 保荐人名称：中信证券股份有限公司 | | | 被保荐公司简称：义翘神州 | | --- | --- | --- | --- | | 保荐代表人姓名：赵陆胤 | | | 联系电话：010-60837513 | | 保荐代表人姓名：焦延延 | | | 联系电话：010-60836950 | | 现场检查人员姓名：赵陆胤、陈一奇 | | | | | 年 月 日至 月 现场检查对应期间：2024 1 1 2024 12 31 | 年 | | 日 | | 现场检查时间：2025 | | 年 月 日 4 18 | | | 一、现场检查事项 | | | 现场检查意见 | | | | | 不适用 | | 现场检查手段： | | | | | 股东、实际控制人、董事、监事、高级管理人员的信息披露文件及相关变更决策 | | | | | 文件，查看上市公司生产经营场所，对上市公司高级管理人员进行访谈。 | | | | | 1.公司章程和公司治理制度是否完备、合规 | | | √ | | 2.公司章程和三会规则是否得到有效执行 | | | √ | | 3.三 ...

中信证券股份有限公司 1 | （1）列席公司股东大会次数 | 无 | | --- | --- | | （2）列席公司董事会次数 | 无 | | （3）列席公司监事会次数 | 无 | | 5.现场检查情况 | | | （1）现场检查次数 | 1次 | | （2）现场检查报告是否按照深圳证券交易所规定 | 是 | | 报送 | | | （3）现场检查发现的主要问题及整改情况 | 无 | | 6.发表专项意见情况 | | | （1）发表专项意见次数 | 5次 | | （2）发表非同意意见所涉问题及结论意见 | 无 | | 7.向深圳证券交易所报告情况（现场检查报告除 | | | 外） | | | （1）向深圳证券交易所报告的次数 | 2次 | | （2）报告事项的主要内容 | 中信证券股份有限公司关于北京义翘神州科技 | | | 股份有限公司2023年年度跟踪报告 | | | 中信证券股份有限公司关于北京义翘神州科技 | | | 股份有限公司2024年半年度跟踪报告 | | （3）报告事项的进展或者整改情况 | 不适用 | | 8.关注职责的履行情况 | | | （1）是否存在需要关注的事项 | 不适用 | | （ ...

中信证券股份有限公司 关于北京义翘神州科技股份有限公司 2024年度持续督导培训情况报告 深圳证券交易所： 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）作为北京义翘 神州科技股份有限公司（以下简称"义翘神州"或"公司"）首次公开发行股票 并在创业板上市的保荐人，根据《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》的相关规定，对义翘神州进行了 2024 年度持续督导培训，报 告如下： 一、本次持续督导培训的基本情况 （一）保荐人：中信证券股份有限公司 （二）保荐代表人：赵陆胤、焦延延 （三）培训时间：2025 年 4 月 18 日 （四）培训地点：公司会议室 （五）培训人员：赵陆胤、陈一奇 （六）培训对象：公司董事、监事、高级管理人员、中层以上管理人员及控 股股东相关人员 （七）培训内容：本次培训内容主要为上市公司规范运作及信息披露，本次 培训涉及的主要法律法规及相关规定包括《中华人民共和国证券法》《深圳证券 交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》《上市公司监管指引第 2 号——上市公司募集资金 管理和使用的监管要求》及上 ...

Revenue and Profit - The company's revenue for Q1 2025 was ¥155,301,016.24, representing a 1.94% increase compared to ¥152,348,904.34 in the same period last year[4] - Net profit attributable to shareholders decreased by 48.27% to ¥22,636,414.00 from ¥43,761,483.94 year-on-year[4] - The net profit after deducting non-recurring gains and losses fell by 58.82% to ¥8,512,522.61 from ¥20,671,508.12 in the previous year[4] - The basic earnings per share decreased by 45.07% to ¥0.1861 from ¥0.3388 in the same period last year[4] - The net profit for the company was CNY 22.64 million, a decrease of 48.27% compared to the previous year, primarily due to fluctuations in financial returns and rising operational costs[16] - Total operating revenue for the current period reached ¥155,301,016.24, a 1.3% increase from ¥152,348,904.34 in the previous period[21] - Net profit for the current period was ¥22,636,414.00, a decrease of 48.3% compared to ¥43,761,483.94 in the previous period[22] - The basic earnings per share for the current period was ¥0.1861, down from ¥0.3388 in the previous period[22] - Total comprehensive income for the current period was ¥17,694,271.03, a decrease from ¥49,800,242.67 in the previous period[22] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥6,052,237,912.80, a slight decrease of 0.04% from ¥6,054,708,956.79 at the end of the previous year[4] - As of March 31, 2025, the total assets of the company were CNY 6.05 billion, slightly down from CNY 6.05 billion at the beginning of the period[20] - The company's total liabilities were CNY 261.25 million, down from CNY 281.80 million at the beginning of the period[20] - The total equity attributable to the parent company was CNY 5.79 billion, an increase from CNY 5.77 billion at the beginning of the period[20] Cash Flow - Cash flow from operating activities decreased by 7.47% to ¥15,857,887.15 from ¥17,137,226.34 year-on-year[4] - Operating cash flow net amount was ¥15,857,887.15, down 7.5% from ¥17,137,226.34 in the previous period[24] - Cash and cash equivalents at the end of the period totaled ¥436,870,744.72, a decrease from ¥1,411,211,371.80 in the previous period[25] - The company reported a significant increase in cash and cash equivalents, rising by 187.90% to ¥671,799,434.97 from ¥233,345,821.82 at the end of the previous year[8] - The net cash flow from financing activities improved by 92.79%, reaching -¥7,877,849.28 compared to -¥109,300,862.18 in the previous year[13] - Investment activities generated a net cash flow of ¥303,364,527.88, compared to ¥315,726,731.35 in the previous period[24] Expenses - Total operating costs increased to ¥147,350,379.90, up 20.2% from ¥122,545,105.64 in the previous period[21] - The financial expenses increased by 125.23% to ¥1,761,710.86 compared to a negative expense of ¥6,983,425.92 in the same period last year[10] - The company reported a significant increase in sales expenses, which rose to ¥41,326,505.64 from ¥38,152,688.73 in the previous period, reflecting a 5.7% increase[21] Other Financial Metrics - The company received government subsidies amounting to ¥1,417,777.05 related to talent projects and other government support[5] - Regular business revenue amounted to CNY 143.28 million, showing a year-on-year growth of 8.61%[16] - Non-regular business revenue was CNY 4.95 million, which declined by 63.42% year-on-year[16] - The company's accounts receivable stood at CNY 145.26 million, slightly down from CNY 150.48 million at the beginning of the period[18] - The company reported a decrease in inventory, which was CNY 63.51 million compared to CNY 64.40 million at the beginning of the period[18] - Other comprehensive income after tax for the current period was -¥4,942,142.97, compared to ¥6,038,758.73 in the previous period[22]